Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Digital content for MaxCyte

    Client Virtual Booth

    MAXCYTE

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    MaxCyte
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    22 Firstfield Road, Suite 110 Gaithersburg, MD 20878
    Telephone
    Telephone
    +1-301-944-1700
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://maxcyte.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/maxcyte-inc-
    Twitter
    Twitter
    https://twitter.com/maxcyte_info?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
    MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024

    https://www.globenewswire.com/news-release/2024/04/10/2860711/0/en/MaxCyte-to-Report-First-Quarter-2024-Financial-Results-on-May-7-2024.html

    GLOBENEWSWIRE
    10 Apr 2024
    Share Share
    MaxCyte Signs Strategic Platform License with Be Biopharma
    MaxCyte Signs Strategic Platform License with Be Biopharma

    https://www.globenewswire.com/news-release/2024/04/02/2855927/0/en/MaxCyte-Signs-Strategic-Platform-License-with-Be-Biopharma-to-Support-the-Development-of-Engineered-B-Cell-Medicines-BCMs.html

    GLOBENEWSWIRE
    02 Apr 2024
    Share Share
    MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results
    MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results

    https://www.globenewswire.com//news-release/2024/03/12/2845016/0/en/MaxCyte-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Reiterates-2024-Guidance.html

    GLOBENEWSWIRE
    12 Mar 2024
    Share Share
    MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results
    MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results

    https://www.globenewswire.com//news-release/2024/03/04/2839956/0/en/MaxCyte-Initiates-Full-Year-2024-Guidance-and-Reaffirms-2023-Preliminary-Results.html

    GLOBENEWSWIRE
    04 Mar 2024
    Share Share
    MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results
    MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results

    https://www.globenewswire.com//news-release/2024/02/09/2826790/0/en/MaxCyte-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-March-12-2024-and-Participate-in-Upcoming-Investor-Conferences.html

    GLOBENEWSWIRE
    09 Feb 2024
    Share Share
    MaxCyte and Wugen Sign Strategic Platform License
    MaxCyte and Wugen Sign Strategic Platform License

    https://www.globenewswire.com/news-release/2024/01/30/2819968/0/en/MaxCyte-and-Wugen-Sign-Strategic-Platform-License-to-Expedite-Scale-Up-of-Clinical-and-Commercial-Manufacturing-of-Wugen-s-Investigational-Allogeneic-Off-the-Shelf-Cell-Therapies-f.html

    GLOBENEWSWIRE
    30 Jan 2024
    Share Share
    MaxCyte Signs Strategic Platform License with Imugene
    MaxCyte Signs Strategic Platform License with Imugene

    https://www.globenewswire.com//news-release/2024/01/23/2814060/0/en/MaxCyte-Signs-Strategic-Platform-License-with-Imugene-to-Advance-their-Cancer-Immunotherapy-Programs.html

    GLOBENEWSWIRE
    23 Jan 2024
    Share Share
    MaxCyte Announces Preliminary Unaudited Fourth Quarter Financial Results
    MaxCyte Announces Preliminary Unaudited Fourth Quarter Financial Results

    https://www.globenewswire.com//news-release/2024/01/08/2805846/0/en/MaxCyte-Announces-Preliminary-Unaudited-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html

    GLOBENEWSWIRE
    08 Jan 2024
    Share Share
    MaxCyte and Lion TCR form Partnership
    MaxCyte and Lion TCR form Partnership

    https://www.globenewswire.com//news-release/2024/01/03/2803278/0/en/MaxCyte-and-Lion-TCR-form-Partnership-to-Support-Global-Expansion-of-Lion-TCR-s-TCR-T-Cell-Pipeline.html

    GLOBENEWSWIRE
    03 Jan 2024
    Share Share
    MaxCyte Confirms Appointment of Maher Masoud as President, CEO and Director
    MaxCyte Confirms Appointment of Maher Masoud as President, CEO and Director

    https://www.globenewswire.com//news-release/2024/01/02/2802418/0/en/MaxCyte-Confirms-Appointment-of-Maher-Masoud-as-President-Chief-Executive-Officer-and-Director.html

    GLOBENEWSWIRE
    02 Jan 2024
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    polpharma-m-2024-04-15

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search